BioCentury
ARTICLE | Company News

ImmunoGen regains rights to DLBCL candidate

April 25, 2015 1:14 AM UTC

ImmunoGen Inc. (NASDAQ:IMGN) said it regained rights to coltuximab ravtansine ( SAR3419) from Sanofi (Euronext:SAN; NYSE:SNY). The humanized CD19 mAb linked to ImmunoGen's DM4 cytotoxic agent met the primary endpoint last year in a Phase II trial to treat diffuse large B cell lymphoma (DLBCL) (see BioCentury Extra, June 2, 2014).

On the company's fiscal 3Q15 conference call, ImmunoGen executives said Sanofi's decision to return rights was a "portfolio decision" and cited the pharma's plans to downsize its oncology R&D division. Sanofi did not respond to inquiries. The companies partnered in 2003 to develop cancer antibodies (see BioCentury Extra, Feb. 11). ...